| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2008 | US20080019963 Antibodies, polypeptides and uses thereof |
| 01/24/2008 | US20080019961 Hedgehog signaling pathway antagonist cancer treatment |
| 01/24/2008 | US20080019957 Topically applied probucol-containing agent with protective and regenerative effect |
| 01/24/2008 | US20080019942 Novel inhibitors of hepatitis c virus replication |
| 01/24/2008 | US20080019927 Compositions and methods for dermally treating neuropathy with minoxidil |
| 01/24/2008 | US20080019926 Lung Surfactant Supplements |
| 01/24/2008 | US20080019922 Quinazoline derivatives, their preparation, their use, and medicaments comprising them |
| 01/24/2008 | US20080019919 Method for optimizing cancer therapy by monitoring maturation of tumor associated vasculature by selenium |
| 01/24/2008 | US20080019918 Medicinal Preparation |
| 01/24/2008 | US20080019916 Methods and pharmaceuticals for treating muscle insulin resistance and related conditions |
| 01/24/2008 | US20080019915 including cystic fibrosis transmembrane conductance regulator ("CFTR"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis |
| 01/24/2008 | US20080019910 Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors |
| 01/24/2008 | US20080017191 Metered dose inhaler |
| 01/24/2008 | US20080016674 Method And Installation Means For Installing An Electrical Machine |
| 01/24/2008 | DE60128472T2 Kombinierte tumortherapie auf der basis von distamycin-acryloylderivaten und alkylierungsmitteln Combined tumor therapy on the basis of distamycin acryloylderivaten and alkylating agents |
| 01/24/2008 | DE102007032613A1 Spiraprilhydrochlorid und polymorphe Formen davon Spirapril hydrochloride and polymorphic forms thereof |
| 01/24/2008 | DE102007032612A1 Polymorphe Formen von Flupirtinmaleat Polymorphic forms of flupirtine maleate |
| 01/24/2008 | DE102006034320A1 Antioxidant, useful for preparation of e.g. coloring agent, vesicle, dermocosmetic, pharmaceuticals and nutrient- or feedstuff, comprises at least an isorenieratene compound |
| 01/24/2008 | DE102006033321A1 Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen Medical use of N-phenylpropenoyl-amino acid derivatives and related compounds |
| 01/24/2008 | DE102006033140A1 Aminoindazolharnstoffderivate Aminoindazolharnstoffderivate |
| 01/24/2008 | DE102006033114A1 Spirocyclische Azaindol-Derivate Spirocyclic azaindole derivatives |
| 01/24/2008 | DE10121982B4 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation |
| 01/24/2008 | CA2820931A1 Novel crystals of substituted phenylalkanoic acid and method of producing the same |
| 01/24/2008 | CA2773177A1 Novel crystals of substituted phenylalkanoic acid and method of producing the same |
| 01/24/2008 | CA2693992A1 Methods of improving the pharmacokinetics of doxepin |
| 01/24/2008 | CA2692440A1 Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| 01/24/2008 | CA2660320A1 Morpholinyl and pyrrolidinyl analogs |
| 01/24/2008 | CA2659754A1 Combination of modafinil and an antagonist or inverse agonist of the h3 receptor |
| 01/24/2008 | CA2659662A1 Concentrated methotrexate solutions |
| 01/24/2008 | CA2659524A1 Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same |
| 01/24/2008 | CA2659155A1 Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1 |
| 01/24/2008 | CA2658976A1 Aminoindazolylurea derivatives |
| 01/24/2008 | CA2658770A1 Composition having effect of treating, preventing, or improving diabetes or diabetic complication and drink comprising the same |
| 01/24/2008 | CA2658768A1 End-modified poly(beta-amino esters) and uses thereof |
| 01/24/2008 | CA2658764A1 Benzothiophene inhibitors of rho kinase |
| 01/24/2008 | CA2658633A1 Chiral compounds substituted with phosphonic acid ester functions or phosphonic acid functions |
| 01/24/2008 | CA2658573A1 Cgrp receptor antagonists |
| 01/24/2008 | CA2658506A1 Acrymalide derivatives as fab 1 inhibitors |
| 01/24/2008 | CA2658484A1 Compositions and methods for vaccinating against hsv-2 |
| 01/24/2008 | CA2658465A1 Liquid compositions of calcium acetate |
| 01/24/2008 | CA2658433A1 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| 01/24/2008 | CA2658404A1 Selective antagonists of a2a adenosine receptors |
| 01/24/2008 | CA2658400A1 Drugs comprising an inhibitor of class 1 alpha mannosidase for the treatment of sarcoglycanopathies |
| 01/24/2008 | CA2658395A1 Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| 01/24/2008 | CA2658382A1 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases |
| 01/24/2008 | CA2658379A1 Spirocyclic azaindole derivatives |
| 01/24/2008 | CA2658376A1 4-heteroaryl-substituted 1-aminocyclohexane-1- and cyclohexane-1-derivatives having effects of the opioid receptor system |
| 01/24/2008 | CA2658361A1 Ophthalmic formulations for the treatment of inflammation |
| 01/24/2008 | CA2658342A1 Therapeutic agent for amyotrophic lateral sclerosis |
| 01/24/2008 | CA2658327A1 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses |
| 01/24/2008 | CA2658273A1 Process for producing arachidonic acid and/or eicosapentaenoic acid in plants |
| 01/24/2008 | CA2658263A1 Thiadiazolidinone derivatives |
| 01/24/2008 | CA2658192A1 Jak inhibitors for treatment of myeloproliferative disorders |
| 01/24/2008 | CA2658190A1 Di-amino-substituted heterocyclic compounds and methods of use |
| 01/24/2008 | CA2658098A1 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| 01/24/2008 | CA2658031A1 Immune response modifier foam formulations comprising imiquimod and a fatty acid |
| 01/24/2008 | CA2657936A1 Antiviral protease inhibitors |
| 01/24/2008 | CA2657931A1 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 01/24/2008 | CA2657930A1 Synthesis of (2s,5r)-5-ethynyl-1-{n-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile |
| 01/24/2008 | CA2657928A1 Methods and medicaments for administration of ibuprofen |
| 01/24/2008 | CA2657913A1 Controlled release formulations and associated methods |
| 01/24/2008 | CA2657821A1 Aza-peptide protease inhibitors |
| 01/24/2008 | CA2657788A1 Polycyclic viral inhibitors |
| 01/24/2008 | CA2657776A1 Triazolyl phenyl benzenesulfonamides |
| 01/24/2008 | CA2657769A1 Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
| 01/24/2008 | CA2657723A1 Non-nucleoside reverse transcriptase inhibitors |
| 01/24/2008 | CA2657716A1 Cholanic acid amides |
| 01/24/2008 | CA2657640A1 Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| 01/24/2008 | CA2657639A1 Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
| 01/24/2008 | CA2657481A1 Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists |
| 01/24/2008 | CA2657346A1 Formulations for benzimidazolyl pyridyl ethers |
| 01/24/2008 | CA2657288A1 Phosphorus derivatives as histone deacetylase inhibitors |
| 01/24/2008 | CA2657280A1 Macrocyclic compounds useful as bace inhibitors |
| 01/24/2008 | CA2657269A1 New indications for direct thrombin inhibitors |
| 01/24/2008 | CA2657266A1 New indications for direct thrombin inhibitors in the cardiovascular field |
| 01/24/2008 | CA2657260A1 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| 01/24/2008 | CA2657258A1 Amino-piperidine derivatives as cetp inhibitors |
| 01/24/2008 | CA2657114A1 Nf-.kappa.b inhibitor |
| 01/24/2008 | CA2657034A1 Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
| 01/24/2008 | CA2656869A1 Macrocyclic lactams |
| 01/24/2008 | CA2656807A1 Early detection and prognosis of colon cancers |
| 01/24/2008 | CA2656715A1 Compounds and compositions as itpkb inhibitors |
| 01/24/2008 | CA2656510A1 Anesthetic compounds |
| 01/24/2008 | CA2655238A1 Milk ingredient enriched in polar lipids and uses thereof |
| 01/24/2008 | CA2653374A1 Modulators of pharmacokinetic properties of therapeutics |
| 01/24/2008 | CA2644047A1 Heterobicyclic carboxamides as inhibitors for kinases |
| 01/23/2008 | EP1881327A2 Diagnosis and treatment of malignant neoplasms |
| 01/23/2008 | EP1881000A1 Conjugates of 2-fluoro-2-deoxy-glucose and their uses as anti cancer agents |
| 01/23/2008 | EP1880998A1 Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands |
| 01/23/2008 | EP1880997A1 Crystal of 1-methylcarbapenem compound |
| 01/23/2008 | EP1880995A1 Method for producing indole derivative having piperidine ring |
| 01/23/2008 | EP1880994A1 Crystal of indole derivative having piperidine ring and process for production thereof |
| 01/23/2008 | EP1880993A1 Nitrogen-containing heterocyclic compound |
| 01/23/2008 | EP1880992A1 Stable modifications of tegaserod hydrogen maleate |
| 01/23/2008 | EP1880744A1 Bisphosphonic acids for the treatment and prevention of osteoporosis |
| 01/23/2008 | EP1880738A1 Medical composition for promotion of skin regeneration |
| 01/23/2008 | EP1880737A1 Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
| 01/23/2008 | EP1880736A1 Releasable linkage and composition containing same |
| 01/23/2008 | EP1880727A2 Topical vaginal pharmaceutical compositions |
| 01/23/2008 | EP1880725A1 Liquid formulation comprising clozapine, quetiapine, a salt of quetiapine and/or olanzapine for oral administration |